Compare SIMO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIMO | BEAM |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.3B |
| IPO Year | 2005 | 2020 |
| Metric | SIMO | BEAM |
|---|---|---|
| Price | $88.85 | $26.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $103.13 | $48.09 |
| AVG Volume (30 Days) | 326.7K | ★ 2.0M |
| Earning Date | 02-04-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ 8.75 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $798,326,000.00 | $55,701,000.00 |
| Revenue This Year | $10.15 | N/A |
| Revenue Next Year | $17.72 | $26.52 |
| P/E Ratio | $30.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.21 | $13.53 |
| 52 Week High | $106.60 | $35.25 |
| Indicator | SIMO | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 56.10 |
| Support Level | $83.34 | $25.53 |
| Resistance Level | $89.26 | $27.87 |
| Average True Range (ATR) | 3.24 | 1.64 |
| MACD | -0.26 | -0.03 |
| Stochastic Oscillator | 41.03 | 61.06 |
Silicon Motion Technology Corp is engaged in developing NAND flash controllers for SSDs and other solid state storage devices. Its only operating segment is to develop NAND flash controllers and SSDs solutions. The company derives revenue from product categories such as Mobile Storage, Mobile Communications, and others. Silicon's geographical segments are Taiwan, the United States, Korea, China, Singapore, Malaysia, and others. The company products are used in Personal Computing, Smartphone/Tablet/CE, Flash Card/USB Flash Drive, Industrial and Embedded, Automotive, and Enterprise and Data centers.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.